Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancerMengmeng Lü, Qing Zhang, Zhen Li et al.|Pharmacological Research|2021Cited by 50
Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy.Qing Zhang, Junnian Zheng, Jiage Ding et al.|PubMed|2019Cited by 44
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCsXiaokang Zhang, Qing Zhang, Shishuo Sun et al.|Journal of Cancer Research and Clinical Oncology|2022Cited by 24
Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive ImmunityHongyan Liu, Qing Zhang, Shishuo Sun et al.|Frontiers in Oncology|2021Cited by 20
Lenvatinib Enhances T Cell Immunity and the Efficacy of Adoptive Chimeric Antigen Receptor-Modified T Cells by Decreasing Myeloid-Derived Suppressor Cells in CancerMengmeng Lü, Qing Zhang, Xiaokang Zhang et al.|SSRN Electronic Journal|2021Cited by 1